August 8, 2016
Meiji Seika Pharma announced on August 4 that it has licensed out the worldwide R&D, manufacturing, and marketing rights to a therapeutic candidate substance (compound No.: CP9531) for a multiple sclerosis treatment to Curadim Pharma, a bioventure established as recently...read more